Infectious Disease In-Vitro Diagnostics Market To Be Driven By Growing Geriatric Population Till 202

Infectious Disease In-vitro Diagnostics Industry Overview

The global infectious disease in-vitro diagnostics market size was valued at USD 56.1 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 3.9% from 2021 to 2028.

The growth can be attributed to the growing geriatric population, technological advancements, and external funding for R&D. Growing prevalence of infectious diseases is also boosting the market growth. The rising demand for PoC testing attributable to government support and rising consumer awareness about faster diagnostics are propelling the demand. Furthermore, the introduction of high-quality and cheap medical solutions for lab automation can be a significant driver for the market.

Gather more insights about the market drivers, restrains and growth of the Global Infectious Disease In-vitro Diagnostics Market

The geriatric population is expected to grow at a fast pace in Latin America, with a 71% increase in the population of 60 years and above, followed by Asia (66%), Africa (64%), North America (41%), and Europe (23%) between 2015 and 2030. Aging is the leading risk factor for the development of diseases, such as cardiovascular and neurological diseases. Therefore, the fact that the global geriatric population is expected to grow over the forecast period is anticipated to be a high-impact rendering driver of the market for infectious diseases in-vitro diagnostics.

Diagnostics for SARS-CoV-2 detection are being continuously launched for catering to markets that have specific regulatory requirements. For instance, in March 2020, the ID Now COVID-19 test by Abbott also received emergency use authorization. In July 2020, NIH invested USD 248.7 million to support the scaling-up of diagnostic test production under its Rapid Acceleration of Diagnostics (RADx) initiative. The launch of new products is continuously increasing competition in the market for infectious diseases in-vitro diagnostics, making the market dynamics and process of choosing products highly complex.

In addition, the growing incidence of STIs, such as HIV and HPV, is expected to provide the market with a large target population. According to the WHO, 37.9 million individuals across the globe were living with HIV infection in 2018. About 1.7 million new cases of HIV were reported in 2018. Moreover, people suffering from HIV are highly susceptible to other infections, such as tuberculosis, which is considered to be the leading cause of death among HIV-affected people. In 2018, 862,000 people with HIV were estimated to be suffering from tuberculosis and 251,000 people suffering from HIV were estimated to have died due to tuberculosis. This prevalence is expected to boost the demand for diagnostics.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• HPV Testing And Pap Test Market - The global HPV testing and Pap test market size was valued at USD 1.7 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 16.4% from 2021 to 2028. Technological advancements, increasing number of cervical cancer screening programs, and high incidence of cervical cancer are some major factors driving the market for HPV testing and Pap test. However, the outbreak of Covid-19 and the implementation of restrictions to stay-at-home across the globe have rigorously reduced routine cancer screenings.

• Lab Automation Market - The global lab automation market size was estimated at USD 4.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.1% from 2021 to 2028. Lab automation uses technology to substitute or streamline the manual manipulation of processes and equipment. Depending on the workflow of a lab the degree of automation is decided.

Infectious Disease In-vitro Diagnostics Market Segmentation

Grand View Research has segmented the global infectious disease in-vitro diagnostics market based on product, technology, application, end-use, and region:

Infectious Diseases IVD Product Outlook (Revenue, USD Million, 2017 - 2028)

• Instruments

  • MRSA

  • Streptococcus

  • Clostridium Difficile

  • VRE

  • CRE

  • Respiratory Virus

  • Candida

  • TB and Drug-resistant TB

  • Gastro-intestinal Panel Testing

  • Chlamydia

  • Gonorrhea

  • HPV

  • HIV

  • Hepatitis C

  • Hepatitis B

  • Covid-19

  • Others

• Reagents

  • MRSA

  • Streptococcus

  • Clostridium Difficile

  • VRE

  • CRE

  • Respiratory Virus

  • Candida

  • TB and Drug-resistant TB

  • Gastro-intestinal Panel Testing

  • Chlamydia

  • Gonorrhea

  • HPV

  • HIV

  • Hepatitis C

  • Hepatitis B

  • Covid-19

  • Others

• Services

  • MRSA

  • Streptococcus

  • Clostridium Difficile

  • VRE

  • CRE

  • Respiratory Virus

  • Candida

  • TB and Drug-resistant TB

  • Gastro-intestinal Panel Testing

  • Chlamydia

  • Gonorrhea

  • HPV

  • HIV

  • Hepatitis C

  • Hepatitis B

  • Covid-19

  • Others

Infectious Diseases IVD Technology Outlook (Revenue, USD Million, 2017 - 2028)

• Immunoassay

• Molecular Diagnostics

• Microbiology

• Others

Infectious Diseases IVD Application Outlook (Revenue, USD Million, 2017 - 2028)

• MRSA

• Streptococcus

• Clostridium Difficile

• VRE

• CRE

• Respiratory Virus

• Candida

• TB and Drug-resistant TB

• Gastro-intestinal Panel Testing

• Chlamydia

• Gonorrhea

• HPV

• HIV

• Hepatitis C

• Hepatitis B

• Covid-19

• Others

Infectious Diseases IVD End-use Outlook (Revenue, USD Million, 2017 - 2028)

• Point of care

• Central Laboratories

• Others

Infectious Diseases IVD Regional Outlook (Revenue, USD Million, 2017 - 2028)

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

Market Share Insights

• April 2020: Mobidiag Ltd. received EUA for Amplidiag COVID-19 for use in clinical laboratories in Finland. The EUA of the product is underway in France, Sweden, and the U.K.

• February 2019: Abbott received CE Mark for DETERMINE HBSAG 2 test for detection and diagnosis of hepatitis B surface antigen.

Key Companies profiled:

Some prominent players in the global infectious disease in-vitro diagnostics market include

• BD

• bioMérieux SA

• Abbott

• Quidel Corporation

• OraSure Technologies, Inc.

• Hologic, Inc. (Gen Probe)

• Danaher

• QIAGEN

• F. Hoffmann-La Roche, Ltd.

• Siemens Healthineers AG

• Bio-Rad Laboratories, Inc.

Order a free sample PDF of the Infectious Disease In-vitro Diagnostics Market Intelligence Study, published by Grand View Research.